Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients

被引:14
|
作者
Ohuchi, Kentaro [1 ]
Kambayashi, Yumi [1 ]
Hidaka, Takanori [1 ]
Fujimura, Taku [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
melanoma; PAI-1; TAMs; Anti-PD1; Abs; efficacy; MACROPHAGES; PROMOTES; CELLS;
D O I
10.3389/fonc.2021.798385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1 expression on melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1 antibodies (Abs). These findings suggested that PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of PAI-1 in melanoma patients were evaluated, and the immunomodulatory effects of PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of PAI-1 showed that PAI-1 expression on melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of PAI-1 were significantly decreased in responders compared to non-responders. Notably, PAI-1 decreased the production of various chemokines from monocyte-derived M2 macrophages in vitro, suggesting that PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of PAI-1 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
    Machiraju, Devayani
    Schaefer, Sarah
    Hassel, Jessica C.
    LIFE-BASEL, 2021, 11 (12):
  • [2] Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
    Shui, Irene M.
    Scherrer, Emilie
    Frederickson, Andrew
    Li, Joyce W.
    Mynzhassarova, Anel
    Druyts, Eric
    Tawbi, Hussein
    MELANOMA RESEARCH, 2022, 32 (06) : 393 - 404
  • [3] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [4] Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
    Huynh, Sandra
    Mortier, Laurent
    Dutriaux, Caroline
    Maubec, Eve
    Boileau, Marie
    Dereure, Olivier
    Leccia, Marie-Therese
    Arnault, Jean-Philippe
    Brunet-Possenti, Florence
    Aubin, Francois
    Dreno, Brigitte
    Beylot-Barry, Marie
    Lebbe, Celeste
    Lefevre, Wendy
    Delyon, Julie
    CANCERS, 2020, 12 (06) : 1 - 11
  • [5] Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
    Chan, Matthew M. K.
    Kefford, Richard F.
    Carlino, Matteo
    Clements, Arthur
    Manoliosz, Nicholas
    JOURNAL OF IMMUNOTHERAPY, 2015, 38 (01) : 37 - 39
  • [6] Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
    Nie, Run-Cong
    Yuan, Shu-Qiang
    Wang, Yun
    Chen, Ying-Bo
    Cai, Yan-Yu
    Chen, Shi
    Li, Shu-Man
    Zhou, Jie
    Chen, Guo-Ming
    Luo, Tian-Qi
    Zhou, Zhi-Wei
    Li, Yuan-Fang
    AGING-US, 2019, 11 (23): : 11576 - 11590
  • [7] Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas
    Ohuchi, Kentaro
    Amagai, Ryo
    Ikawa, Tetsuya
    Muto, Yusuke
    Roh, Yuna
    Endo, Junko
    Maekawa, Takeo
    Kambayashi, Yumi
    Asano, Yoshihide
    Fujimura, Taku
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (01) : 50 - 59
  • [8] Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
    Nakamura, Y.
    Namikawa, K.
    Yoshino, K.
    Yoshikawa, S.
    Uchi, H.
    Goto, K.
    Fukushima, S.
    Kiniwa, Y.
    Takenouchi, T.
    Uhara, H.
    Kawai, T.
    Hatta, N.
    Funakoshi, T.
    Teramoto, Y.
    Otsuka, A.
    Doi, H.
    Ogata, D.
    Matsushita, S.
    Isei, T.
    Hayashi, T.
    Shibayama, Y.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1198 - 1206
  • [9] Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
    Brown, Lauren J.
    Weppler, Alison
    Bhave, Prachi
    Allayous, Clara
    Patrinely, J. Randall, Jr.
    Ott, Patrick
    Sandhu, Shahneen
    Haydon, Andrew
    Lebbe, Celeste
    Johnson, Douglas B.
    Long, Georgina V.
    Menzies, Alexander A.
    Carlino, Matteo S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)
  • [10] How anti-PD1 treatments are changing the management of melanoma
    Hersey, Peter
    Kakavand, Hojabr
    Wilmott, James
    van der Westhuizen, Andre
    Gallagher, Stuart
    Gowrishankar, Kavitha
    Scolyer, Richard
    MELANOMA MANAGEMENT, 2014, 1 (02) : 165 - 172